

Commercial/Healthcare Exchange Step Criteria Effective: September 14, 2021

Step Therapy Name: Brexafemme

Step 1 Agent(s): Fluconazole 150 mg oral tablet

Step 2 Agent(s): Brexafemme (Ibexafungerp) oral tablet

Medication/Class Description: Vulvovaginal Candidiasis medications are indicated for the treatment of vulvovaginal candidiasis with symptoms of abnormal discharge, and burning, redness, swelling, and itching in the vulva and vagina. The available products are largely azole antifungals that inhibiting lanosterol 14-alpha demethylase, which converts lanosterol to ergosterol, the main sterol in the fungal cell wall. The depletion of ergosterol damages the cell wall leading to cell death. The only novel oral antifungal (ibexafungerp) for the treatment of vulvovaginal candidiasis is a triterpenoid antifungal drug. The triterpenoid antifungal inhibits glucan synthase, an enzyme involved in the formation of 1,3-β-D-glucan, an essential cell wall component, ultimately leading to cell lysis.

Required Medical Information:

1. Diagnosis
2. Previous therapies tried and failed

Age Restrictions: None

Prescriber Restrictions: None

Coverage Duration:

Exceptions for Stepped Medications

1. Patient has had a trial and failure of one Step 1 Agent; OR
2. Patient has an intolerance or contraindication to one Step 1 Agent(s), defined as (but not limited to):
 - A. Allergic reaction;
 - B. Adverse drug reactions

References:

1. Brexafemme[®] tablets [prescribing information]. Jersey City, NJ: Scynexis, June 2021.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	9/14/2021